Ultragesic (tramadol + paracetamol): Uses, Dosage & Side Effects

What it's for (Indications)

Tramadol + Paracetamol is indicated for the management of moderate to moderately severe pain.
This combination analgesic is particularly useful when the concurrent use of an opioid analgesic and a non-opioid analgesic is deemed necessary to provide effective pain relief that cannot be adequately managed by alternative treatments.
Its primary role is in situations requiring a more potent analgesic effect than single-agent non-opioids, but where a strong opioid might be excessive.
The unique dual mechanism of action, combining opioid agonism with central inhibitory effects on pain transmission, allows for comprehensive pain management across various etiologies, including postoperative pain, chronic musculoskeletal pain, and neuropathic pain components, thereby improving patient comfort and functional outcomes.

Dosage Information

Type	Guideline
Standard	The standard adult dosage for tramadol + paracetamol typically involves one to two tablets every 4 to 6 hours as needed for pain, not exceeding eight tablets (equivalent to 300 mg tramadol and 2600 mg paracetamol for a 37.5 mg/325 mg formulation) in any 24-hour period. Dosage adjustments are crucial for specific patient populations. For patients with creatinine clearance less than 30 mL/min, the dosing interval should be extended, generally not exceeding two tablets every 12 hours. Similarly, in patients with hepatic impairment, the dosage should be carefully titrated, often starting at a lower dose and extending the interval, due to reduced drug clearance. Elderly patients (over 75 years) may also require reduced dosages and extended intervals owing to age-related physiological changes that affect metabolism and excretion. The lowest effective dose for the shortest duration consistent with individual patient treatment goals should always be employed to minimize risks.

Type

Guideline

Standard

The standard adult dosage for tramadol + paracetamol typically involves one to two tablets every 4 to 6 hours as needed for pain, not exceeding eight tablets (equivalent to 300 mg tramadol and 2600 mg paracetamol for a 37.5 mg/325 mg formulation) in any 24-hour period. Dosage adjustments are crucial for specific patient populations. For patients with creatinine clearance less than 30 mL/min, the dosing interval should be extended, generally not exceeding two tablets every 12 hours. Similarly, in patients with hepatic impairment, the dosage should be carefully titrated, often starting at a lower dose and extending the interval, due to reduced drug clearance. Elderly patients (over 75 years) may also require reduced dosages and extended intervals owing to age-related physiological changes that affect metabolism and excretion. The lowest effective dose for the shortest duration consistent with individual patient treatment goals should always be employed to minimize risks.

Safety & Warnings

Common Side Effects

Commonly reported adverse effects associated with tramadol + paracetamol include nausea, dizziness, somnolence, constipation, headache, and vomiting, reflecting the central nervous system effects of tramadol.
Less common but significant side effects encompass pruritus, diarrhea, dyspepsia, dry mouth, and sweating.
More serious, though rare, adverse reactions demand immediate medical attention.
These include severe respiratory depression, which can be life-threatening; seizures, particularly in patients with pre-existing epilepsy or those on medications lowering the seizure threshold; serotonin syndrome, characterized by mental status changes, autonomic instability, and neuromuscular abnormalities, especially when co-administered with serotonergic drugs; and severe allergic reactions such as anaphylaxis.
Additionally, hepatotoxicity due to the paracetamol component can occur, particularly with supratherapeutic doses or in patients with compromised liver function.
Patients should be educated on recognizing these symptoms and seeking urgent medical care if they arise.

Serious Warnings

Black Box Warning: **WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYP2D6 ULTRARAPID METABOLISM; HEPATOTOXICITY; AND INTERACTIONS WITH CNS DEPRESSANTS.** **Addiction, Abuse, and Misuse:** Tramadol + Paracetamol exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions. **Life-Threatening Respiratory Depression:** Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation or following a dosage increase. **Accidental Ingestion:** Accidental ingestion of even one dose, especially by children, can result in a fatal overdose of tramadol. **Neonatal Opioid Withdrawal Syndrome:** Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. **CYP2D6 Ultrarapid Metabolism:** Ultrarapid metabolizers of tramadol due to a CYP2D6 polymorphism are at increased risk for life-threatening respiratory depression. Tramadol is contraindicated in children younger than 12 years of age and in children younger than 18 years following tonsillectomy and/or adenoidectomy. **Hepatotoxicity:** Acetaminophen (paracetamol) has been associated with cases of acute liver failure, sometimes resulting in liver transplant or death. Most cases of liver injury are associated with the use of acetaminophen at doses exceeding 4000 mg per day and often involve more than one acetaminophen-containing product. **Interactions with CNS Depressants:** Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Careful consideration and patient monitoring are imperative when prescribing tramadol + paracetamol due to several significant warnings.
Patients should be thoroughly counselled regarding the risk of addiction, abuse, and misuse of tramadol, which can lead to overdose and death.
Physical dependence and withdrawal symptoms may occur upon abrupt discontinuation or rapid dosage reduction.
Due to the tramadol component, there is a potential for respiratory depression, which is particularly concerning in elderly, debilitated, or severely ill patients.
The risk of seizures is increased in patients with a history of epilepsy, those on other seizure-threshold-lowering medications, or individuals experiencing withdrawal from drugs or alcohol.
Serotonin syndrome is a serious, potentially fatal condition that can manifest when tramadol is co-administered with other serotonergic agents (e.
g.
, SSRIs, SNRIs, tricyclic antidepressants), requiring prompt recognition and management.
Additionally, the paracetamol component carries a significant risk of acute liver failure, especially with doses exceeding the recommended maximum, concurrent alcohol use, or pre-existing liver disease.
Cases of hypoglycemia have been reported with tramadol, necessitating monitoring in diabetic patients.
Adrenal insufficiency and androgen deficiency are rare but serious endocrine effects associated with chronic opioid use.
Patients should be warned against concurrent use with alcohol or other central nervous system depressants due to enhanced sedative effects and increased risk of respiratory depression.

How it Works (Mechanism of Action)

Tramadol + Paracetamol exerts its analgesic effects through a synergistic combination of two distinct pharmacological mechanisms. Tramadol, a centrally acting opioid analgesic, functions primarily as a weak agonist at the mu-opioid receptor. This action inhibits pain signal transmission by binding to these receptors in the brain and spinal cord. Furthermore, tramadol uniquely enhances the analgesic effect by inhibiting the reuptake of norepinephrine and serotonin within the central nervous system, thereby augmenting the descending inhibitory pain pathways. Paracetamol (acetaminophen), on the other hand, is a non-opioid analgesic and antipyretic whose precise mechanism is not fully elucidated but is believed to involve the inhibition of prostaglandin synthesis, primarily within the central nervous system, possibly through inhibition of cyclooxygenase (COX) enzymes, particularly COX-2. It may also modulate the endogenous cannabinoid system and nitric oxide pathways. The combination of these two agents provides additive and synergistic pain relief, allowing for lower doses of each component to achieve efficacy, potentially reducing the incidence and severity of dose-dependent adverse effects compared to higher doses of either drug alone, thus offering a comprehensive approach to pain management.